O-1602 – 10 mg

Brand:
Cayman
CAS:
317321-41-8
Storage:
-20
UN-No:
De Minimis - 1231 / 3

O-1602 is an agonist of GPR55 (EC50 = 13 nM in a GTPγS binding assay) and a derivative of the GPR55 agonist abnormal cannabidiol (Item No. 10004259).{17583} It is selective for GPR55 over cannabinoid (CB) receptor 1 (CB1) and CB2 (EC50s = >30 µM for both in GTPγS binding assays). O-1602 (50 µM) reduces growth of Mz-ChA-1, HuCCT-1, CC-LP-1, and SG231 cholangiocarcinoma cells and reduces tumor growth in a Mz-ChA-1 mouse xenograft model when administered at a dose of 10 mg/kg per day.{38346} O-1602 increases calcium mobilization and lipogenesis in 3T3-L1 adipocytes in a concentration-dependent manner and increases food intake and fat mass in rats; however, this effect was also observed in mice lacking GPR55.{38347} O-1602 reduces movement-induced firing of nociceptive C fibers in a rat model of inflammatory joint pain.{38344} It also decreases IL-6 and TNF-α levels and myeloperoxidase activities in the plasma, lungs, and pancreas in a mouse model of acute pancreatitis.{38345}  

 

Available on backorder

SKU: 10006803 - 10 mg Category:

Description

An agonist of GPR55 (EC50 = 13 nM in a GTPγS binding assay); selective for GPR55 over CB1 and CB1 receptors (EC50s = >30 µM for both in GTPγS binding assays); reduces growth of Mz-ChA-1, HuCCT-1, CC-LP-1, and SG231 cholangiocarcinoma cells at 50 µM; reduces tumor growth in a Mz-ChA-1 mouse xenograft model at 10 mg/kg per day; increases food intake and fat mass in rats in a GPR55-independent manner; reduces movement-induced firing of nociceptive C fibers in a rat model of inflammatory joint pain


Formal name: 5-methyl-4-[(1R,6R)-3-methyl-6-(1-methylethenyl)-2-cyclohexen-1-yl]-1,3-benzenediol

Synonyms:  Abn-CBDO|Abnormal Cannabidiorcin|Abnormal Cannabidiorcinol|Abnormal Cannabiorcodiol

Molecular weight: 258.4

CAS: 317321-41-8

Purity: ≥98%

Formulation: A solution in methyl acetate


Product Type|Biochemicals|Receptor Pharmacology|Agonists||Research Area|Cancer||Research Area|Endocrinology & Metabolism|Metabolic Diseases|Obesity||Research Area|Immunology & Inflammation||Research Area|Neuroscience|Behavioral Neuroscience|Food Intake||Research Area|Neuroscience|Cannabinoid Research||Research Area|Neuroscience|Pain Research